Search
Ovid Therapeutics Inc
OVIDAdd to Watchlist
2.690USD
+0.010+0.37%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
449.95MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-02The current earnings forecast score of Ovid Therapeutics Inc is 9.00, ranking 17 out of 387 in the Biotechnology & Medical Research industry. The average price target is 5.00, with a high of 7.00 and a low of 2.00.
Analyst Rating
Based on
10
analysts
Strong Buy
Current Rating
5.500
Target Price
+105.22%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
562
Total
5
Median
6
Average
Company name
Ratings
Analysts
Ovid Therapeutics Inc
OVID
10
CRISPR Therapeutics AG
CRSP
27
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
113
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Ovid Therapeutics Inc's price target?
Analysts forecast that Ovid Therapeutics Inc's price target is USD 5.00, with the highest forecast at USD 7.00 and the lowest forecast at USD 2.00.
How have Ovid Therapeutics IncOVID's recent earnings per share performed?
The market expectation was USD -0.12, while Ovid Therapeutics IncOVID's earnings per share (EPS) for the previous quarter was USD 0.12. EPS for the next quarter is expected at USD -0.12.
What is the analyst rating for Ovid Therapeutics Inc?
Based on the ratings of Ovid Therapeutics Inc's stock from 10 analysts, most analysts support a STRONG BUY trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as STRONG BUY. Please note that this is not trading advice. You still need to conduct your own analysis.